Larimar Therapeutics (LRMR) EBIT (2016 - 2020)
Historic EBIT for Larimar Therapeutics (LRMR) over the last 7 years, with Q1 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' EBIT rose 7316.41% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 3877.03%. This contributed to the annual value of -$45.7 million for FY2019, which is 2530.68% up from last year.
- According to the latest figures from Q1 2020, Larimar Therapeutics' EBIT is -$3.6 million, which was up 7316.41% from -$7.3 million recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' EBIT ranged from a high of -$3.6 million in Q1 2020 and a low of -$17.9 million during Q1 2016
- Over the past 5 years, Larimar Therapeutics' median EBIT value was -$13.4 million (recorded in 2017), while the average stood at -$13.0 million.
- Per our database at Business Quant, Larimar Therapeutics' EBIT plummeted by 3487.16% in 2016 and then skyrocketed by 7316.41% in 2020.
- Larimar Therapeutics' EBIT (Quarter) stood at -$10.5 million in 2016, then fell by 27.52% to -$13.4 million in 2017, then decreased by 9.98% to -$14.7 million in 2018, then soared by 50.44% to -$7.3 million in 2019, then soared by 51.06% to -$3.6 million in 2020.
- Its EBIT was -$3.6 million in Q1 2020, compared to -$7.3 million in Q4 2019 and -$12.9 million in Q3 2019.